亨迪藥業(301211.SZ):布洛芬混懸液獲得藥品註冊證書
格隆匯6月9日丨亨迪藥業(301211.SZ)公佈,公司於近日收到國家藥品監督管理局核准簽發的《藥品註冊證書》。布洛芬混懸劑,主要成分為布洛芬,屬於非甾體抗炎藥。其核心作用退熱、止痛、抗炎,藥物微粒均勻分散在液體中,是兒童退燒止痛的常用且有效的藥物,對於吞嚥片劑或膠囊困難的人(如術後、老人或有吞嚥障礙者)也可使用。
布洛芬混懸劑註冊分類為化學藥品4類,按照與參比製劑質量和療效一致的技術要求審評並獲批,批准後視同通過仿製藥質量和療效一致性評價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.